Revenues grew 37% YoY to | 2252 crore (I-direct estimate: | 2126 crore) mainly due to consolidation of the Triad pharmacy business. Excluding Triad, revenues grew 17% YoY EBITDA margins improved 175 bps YoY to 20.3% (I-direct estimate: 21.2%) mainly due to higher margins in speciality injectable business, which was partly offset by losses in the Triad business Net profit increased a mere 3% to | 155 crore (I-direct estimate: | 250 crore). The growth was impacted due to | 91 crore one-off...